HYDASE (hyaluronidase) by Halozyme Therapeutics is agent, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Approved for dehydration. First approved in 2005.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
HYDASE (hyaluronidase) is an injectable enzyme that modifies connective tissue permeability by hydrolyzing hyaluronic acid, a polysaccharide in the intercellular matrix. It facilitates absorption of injected fluids and localized fluid collections by temporarily decreasing viscosity of cellular cement. The drug is used as an adjunctive agent to enhance dispersion and absorption of co-injected or localized substances.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and shift from growth to lifecycle management roles.
agent, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also…
Worked on HYDASE at Halozyme Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moHalozyme Therapeutics is hiring 2 roles related to this product
Working on HYDASE offers roles primarily in commercial and manufacturing functions, with 12 active job openings reflecting a mature product requiring field salesforce and operational teams. As the product approaches LOE, career moves emphasize supply chain optimization, regional sales management, and manufacturing engineering rather than growth-stage innovation roles.
12 open roles linked to this drug